Oncolytics Biotech stock heads toward a November 19 board vote
Published on 10/07/2026 at 05:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Oncolytics Biotech stock closed at USD 0.60 on October 5, 2026, while the clinical-stage oncology company prepares for a November 19 shareholder vote. The meeting is set to decide on seven director nominees and several governance proposals, according to StockTitan.
Seven directors face the vote
The board currently has nine members, but the proxy statement proposes a seven-member board after Angela Holtham and Wayne Pisano complete their terms. The virtual annual meeting is scheduled for November 19, 2026, at 4:00 p.m. ET, with votes also covering auditor ratification, executive compensation and the frequency of future compensation votes.
The governance change arrives as Oncolytics advances pelareorep through clinical studies in gastrointestinal cancers. The company is seeking regulatory approval for applications including colorectal, anal and pancreatic cancer, according to its investor-relations overview.
REO 033 supplies the operating catalyst
Oncolytics reported that substantially all planned sites for Part A of its randomized REO 033 colorectal cancer study had been activated, with interim data targeted for year-end 2026. The study is designed to enroll 60 patients across two treatment arms and compares pelareorep plus FOLFIRI and bevacizumab with the standard regimen alone, as StockTitan reported.
The earlier REO 022 study recorded a 33 percent objective response rate and median progression-free survival of 16.6 months. Those figures came from a small, non-randomized study, so the randomized REO 033 readout is the more important checkpoint for the investment case.
Losses and liquidity remain central
For the six months ended June 30, 2026, Oncolytics reported revenue of USD 0, a net loss of USD 18.7 million and operating cash use of USD 15.4 million. The comparable prior-year net loss was USD 10.0 million, while cash and cash equivalents fell to USD 4.1 million from USD 10.7 million, according to MetaTrader.
That financing profile gives the clinical milestones a second dimension: trial progress must compete with capital needs. A separate analyst update from Globe and Mail said H.C. Wainwright maintained a Buy rating with a USD 5.00 price target.
Stock remains far below yearly high
Oncolytics shares had a 52-week range of USD 0.58 to USD 1.39 as of October 6, 2026. The USD 0.60 price was 56.83 percent below the yearly high, while market capitalization stood at USD 60.0 million and trading volume reached 858,511 shares on October 6.
The next hard checkpoint is the November 19 annual meeting, followed by the year-end REO 033 interim update. For investors, the combination of clinical execution, financing capacity and governance changes defines the stock's near-term risk profile.
Oncolytics Biotech stock facts
- Company: Oncolytics Biotech Inc.
- Ticker: ONCY
- Trading venue: Nasdaq
- Price (as of October 5, 2026): USD 0.60, closing price
- Market capitalization: USD 60.0 million (as of October 6, 2026)
- 52-week range: USD 0.58-1.39 (as of October 6, 2026)
- Sector / Industry: Health Care / Biotechnology
